Avalyn to Present AP01 for Pulmonary Fibrosis at ERS Congress 2024

Avalyn Pharma Inc., a biopharmaceutical company in the clinical-stage focused on the development of inhaled therapies for severe pulmonary diseases, has announced its participation in the upcoming European Respiratory Society (ERS) International Congress 2024. This significant event will take place in Vienna, Austria, from September 7-11, 2024, and will feature multiple poster presentations from Avalyn.

The company is set to present the design of its Phase 2b MIST study for AP01 (inhaled pirfenidone) intended for the treatment of progressive pulmonary fibrosis (PPF). Additionally, Avalyn will discuss post-hoc analyses from the ATLAS trial, which evaluated AP01 in patients with idiopathic pulmonary fibrosis (IPF).

The abstracts for Avalyn’s presentations are accessible through the ERS International Congress 2024 online program, and the details of the presentations are as follows:

1. Inhalation Innovation: Phase 2b Study Design on Inhaled Pirfenidone in the Treatment of Progressive Pulmonary Fibrosis
- Authors: Martin Kolb, Colin Reisner, Deepthi Nair, Felix Woodhead, Howard Lazarus, Craig Conoscenti
- Session: PS-28, Poster #: PA690
- Date and Time: September 8, 2024, from 8:00 am to 9:30 am CEST

2. Cough adverse events and FVC decline in the ATLAS study of Inhaled Pirfenidone (AP01) in Idiopathic Pulmonary Fibrosis
- Authors: Nazia Chaudhuri, Barnaby Hirons, Felix Woodhead, Allison Trucillo, Hao Bao, Deepthi Nair, Colin Reisner, Andrey Pavlov, Craig Conoscenti, Howard Lazarus, Surinder Birring
- Session: PS-27, Poster #: PA685
- Date and Time: September 8, 2024, from 8:00 am to 9:30 am CEST

3. Correlation of Early Cough with Disease Activity measured by High-resolution CT in ATLAS: a Phase 1b Study of Inhaled Pirfenidone in Idiopathic Pulmonary Fibrosis
- Authors: Grace Kim, Jonathan Goldin, Felix Woodhead, Deepthi Nair, Howard Lazarus, Craig Conoscenti
- Session: PS-28, Poster #: PA691
- Date and Time: September 8, 2024, from 8:00 am to 9:30 am CEST

4. Association between Functional Improvement and Structural Changes in Quantitative High-resolution CT in ATLAS: a Phase 1b Study of Inhaled Pirfenidone in Idiopathic Pulmonary Fibrosis
- Authors: Grace Kim, Jonathan Goldin, Deepthi Nair, Felix Woodhead, Craig Conoscenti, Howard Lazarus
- Session: PS-28, Poster #: PA692
- Date and Time: September 8, 2024, from 8:00 am to 9:30 am CEST

Avalyn Pharma Inc. is dedicated to the development of inhaled treatments for rare respiratory conditions such as pulmonary fibrosis and other interstitial lung diseases (ILD). Pulmonary fibrosis leads to scarring within the lung tissue, causing a decline in lung function, reduced exercise capacity, and worsening quality of life, alongside a higher mortality rate. The current therapeutic options, while slowing the disease's progression, come with considerable toxicities that limit their use and dosage.

To address these challenges, Avalyn is innovating by developing new inhaled formulations of approved medicines intended to minimize systemic exposure and deliver the treatment directly to the lungs. The company's leading program, AP01, is an enhanced inhaled formulation of pirfenidone, which has demonstrated clinical proof-of-concept in 150 individuals with various forms of pulmonary fibrosis, showing improved efficacy and safety compared to existing therapies. Furthermore, Avalyn has started a Phase 1b study for its second program, AP02, which involves inhaled nintedanib for treating idiopathic pulmonary fibrosis.

Avalyn Pharma Inc. continues to pave the way in respiratory disease treatment innovation, seeking to provide more effective and safer therapeutic options for patients with these debilitating conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!